TY  - JOUR

T1  - The Utility Of Minimal Residual Disease (MRD) Assessment At First Relapse: Results From The BSBMT/Ukmf Myeloma X (Intensive) Trial

JO  - Blood

PY  - 2013/11/15

AU  - Ashcroft J

AU  - de Tute RM

AU  - Cairns DA

AU  - Fletcher M

AU  - Owen RG

AU  - Rawstron A

AU  - O'Connor SJM

AU  - Williams CD

AU  - Snowden JA

AU  - Cavenagh JD

AU  - Parrish C et al

ED  - 

DO  - DOI: 10.1182/blood.v122.21.3378.3378

PB  - American Society of Hematology

VL  - 122

IS  - 21

SP  - 3378

EP  - 3378

Y2  - 2024/12/22

ER  -